anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Somatropin is a human growth hormone (GH) produced by recombinant DNA technology using Escherichia coli. The protein is comprised of 191 amino acid residues and has a molecular weight of about 22,124 daltons. The amino acid sequence is identical to that of human growth hormone of pituitary origin.

ZOMACTON (somatropin) for injection is a sterile, white lyophilized powder, intended for subcutaneous injection after reconstitution with the accompanying diluent.

ZOMACTON 5 mg single-patient-use vial contains 5 mg of somatropin and mannitol (30 mg). Each 5 mg vial is co-packaged with a 5 mL vial of diluent containing Bacteriostatic Sodium Chloride Injection, USP, with 0.9% benzyl alcohol as a preservative, and Water for Injection, USP.

ZOMACTON 10 mg single-patient-use vial contains 10 mg of somatropin, mannitol (10 mg), dibasic sodium phosphate (1.415 mg), and monobasic sodium phosphate (0.608 mg). Each 10 mg vial is co-packaged with a 1 mL syringe of diluent containing Bacteriostatic Water for Injection, USP with 0.33% metacresol as a preservative.

Reconstituted solutions have a pH in the range of 7 to 9.
Metabolic products are recovered from bacterial or mould cultures in a process which comprises adding a specific antiserum to a culture medium to precipitate or agglutinate the bacteria or mould cells, separating the precipitated or agglutinated cells from the culture medium and recovering the desired metabolic product from the separate cells or from the culture liquid.  The process is suitable for the recovery of Vitamin B12 from cultures of Propionibacterium freudenreichii, Bacillus megatherium and strains of Streptomyces, the recovery of streptomycin from strains of Streptomyces, the recovery of bacitracin from B. licheniformis and B. subtilis spp. Tracy 1, and for the recovery of Vitamin B12 from Clostridium acetobutylicum in acetone/butanol fermentations.  The antiserum may be obtained by injecting an animal with increasing concentrations of the bacterium over a series of days and recovering the antiserum from the animal. In an example Vitamin B12 is obtained by adding a specific antiserum for Propionibacterium freudenreichii to a fermentation broth containing cells of that organism, separating the bacterial cells and liquid by centrifugation, extracting the Vitamin B12 from the cells by treatment under acid conditions, purifying the Vitamin B12 by extraction into an organic solvent and re-extraction into an aqueous phase and recovering the purified Vitamin B12.  The example also indicates that optimum agglutination occurs at serum/serum +broth dilutions in the range 1:10,000 to 1:15,000.  The process may be employed in the production of bacitracin, the acidified liquid remaining after the cells of B. subtilis have been removed, being extracted with an organic solvent such as butanol, followed by the adsorption of impurities on charcoal, and recovery of the bacitracin by evaporation under reduced pressure.ALSO:An anti-serum for a specific bacterium is obtained by inoculating an animal, for example a rabbit, horse, cow or ox, with increasing concentrations of the bacterium over a period of days.  When the antibody titre of the blood is sufficiently high, blood is withdrawn and the serum separated from the coagulated cells by conventional methods.  This process is illustrated by the production of an anti-serum specific for Propionibacterium freudenreichii by inoculating a horse.  The anti-sera so obtained are utilized in the precipitation of bacteria or mould cells in fermentation process for the production of metabolic products, e.g. Vitamin B12 and bacitracin.
Following specific inclusion and exclusion criteria (see Eligibility Criteria), participants will be recruited from residential care facilities or day centers. For the acute effects study (cross-over study), participants will randomly perform two resistance training sessions separated by one week of rest: i) one session with one set and ii) another session of three sets. The intensity of the exercises, number of repetitions, type and order of exercises, movement velocity, and rest time between exercises will be the same in both groups. Before, immediately after, and 72 hours after the sessions, a battery of tests will be applied to evaluate the changes in blood pressure, heart rate, tympanic temperature, medicine ball throw distance, five-repetition sit-to-stand time, and handgrip strength. Afterward, participants will be randomly assigned into a one-set or three-set group to perform an eight-week resistance training intervention. As for the acute effects study, the prescription of the other acute training variables will be the same for both groups. A control group (without any form of physical exercise), recruited at the beginning of the research project, will also be part of the study. Before and after the intervention, a battery of tests will be applied to determine the training program's impact on cognitive function, oxidative stress, immunological response, lipid profile, glycemic status, liver function, muscle function, hemodynamic response, and physical performance in individuals with mild cognitive impairment.
All patients diagnosed with ACC underwent 68Ga-PSMA PET/CT scan. If the PET/CT showed high PSMA expression in tumor lesions of some patients, they would intravenously injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 for therapy.
The invention discloses a Chinese medicinal preparation for treating diabetic retinopathy. The diabetic retinopathy belongs to blurred vision, sudden blind, vitreousopacity and the like in medicines. The key to diagnosis and treatment is mentioned that if three types of diabetes are occurred for a long time, essence and blood are deficient, or the eyes cannot see, or the hands are feet are disabled. At present, the Chinese medicine doctors coherently think that the disease is the deteriorated case caused by the symptoms of long-term morbidity, deficiency of yin and body fluid and less nourishment of the eyes. According to the Chinese medicinal preparation, the Chinese medicines including asiatic bilberry, cortex acanthopanacis, radix polygonati officinalis, the root bark of white mulberry, semen Cuscutae, raspberry, Chinese flowering crabapple, hairy triumfetta, ceratostigma root, rhizoma sparganii, whorledleaf solomonseal rhizome, wolfberry fruit and liquorice, are decocted with water to prepare decoction. The clinical test shows that the total effective rate is up to 1.43 percent, the curative effect is good, and poor reaction in the treatment group is avoided.
SUMMARYHealthcare-associated infections (HAIs) represent a burden for public health with a high prevalence and high death rates associated with them. Pathogens with a high potential for antimicrobial resistance, such as ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) and Clostridioides difficile, are responsible for most HAIs. Despite the implementation of infection prevention and control intervention, globally, HAIs prevalence is stable and they are mainly due to endogenous pathogens. It is undeniable that complementary to infection prevention and control measures, prophylactic approaches by active or passive immunization are needed. Specific groups at-risk (elderly people, chronic condition as immunocompromised) and also healthcare workers are key targets. Medical procedures and specific interventions are known to be at risk of HAIs, in addition to hospital environmental exposure. Vaccines or monoclonal antibodies can be seen as attractive preventive approaches for HAIs. In this review, we present an overview of the vaccines and monoclonal antibodies in clinical development for prevention of the major bacterial HAIs pathogens. Based on the current state of knowledge, we look at the challenges and future perspectives to improve prevention by these means.
A water-releasing cosmetic composition in the form of an emulsion and process for preparing the cosmetic composition are provided. The cosmetic composition includes an aqueous phase and an oil phase. The aqueous phase includes a hydrating agent at a concentration, by weight, of about 1% to about 50%. The oil phase includes a silicone polymer, an emulsifying crosslinked siloxane elastomer, a hydrophobic silica and a co-emulsifier. The emulsifying crosslinked siloxane elastomer is at a concentration, by weight, of about 3%-20%, based upon weight of the composition. The hydrophobic silica is at a concentration, by weight, of about 0.1%-5%, based upon weight of the composition. The co-emulsifier is at a concentration, by weight, of about 0.01%-1%, based upon weight of the composition. The cosmetic composition converts from an emulsion to a plurality of droplets upon rubbing.
The invention discloses a preparation method of lycium ruthenicum fermentation liquor, which comprises the following steps: mixing the lycium ruthenicum dry powder with water to obtain a fermentation initial system; adding enzyme into the initial fermentation system for enzymolysis to obtain Lycium ruthenicum fermentation stock solution; adding zymophyte, and fermenting to obtain Lycium ruthenicum Murr fermentation liquid. The preparation method disclosed by the invention furthest reserves the functional components and the activity of the raw materials, avoids the loss of the active components caused by an extraction method, has better free radical scavenging capacity and tyrosinase inhibition capacity, and can be widely applied to cosmetics such as whitening, aging resistance and the like. The preparation method disclosed by the invention is simple in preparation process and low in cost, can realize industrial production, and ensures the stability of product quality. The invention also discloses lycium ruthenicum fermentation liquor prepared by the preparation method of the lycium ruthenicum fermentation liquor. The invention also discloses application of the lycium ruthenicum fermentation liquor in cosmetics. The invention also discloses application of the lycium ruthenicum fermentation liquor in whitening and/or anti-aging cosmetics.
Conventional program will be carried out three sessions per week during the six weeks. Cervical mobilization techniques (glidings-grade 2) of cyriax will be applied in the direction of lateral flexion and rotation. Stretching exercises, craniovertebral flexion exercise and scapulothoracic strengthening exercises will be performed.
Six young (18-30 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
WYMZYA Fe is a combinational contraceptive containing the progestational compound norethindrone and the estrogenic compound ethinyl estradiol. The packaging includes 21 white tablets composed of norethindrone and ethinyl estradiol followed by 7 brown ferrous fumarate (placebo) tablets. The chemical name for norethindrone is 17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one and for ethinyl estradiol the chemical name is 19-nor-17α-pregna-1,3,5(10)-trien-20-yne-3,17-diol. The structural formulas are:

The active white WYMZYA Fe tablets contain 0.4 mg norethindrone and 0.035 mg ethinyl estradiol, and the following inactive ingredients: lactose anhydrous, magnesium stearate, mannitol, microcrystalline cellulose, povidone, sodium starch glycolate, sucralose, vanillin and vitamin E.

The brown tablets contain ferrous fumarate, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate and sucrose. The ferrous fumarate tablets do not serve any therapeutic purpose.

FDA approved dissolution test specifications differ from USP.
Participants received 160 mg enzalutamide orally once daily during double-blind treatment period until radiographic progression was documented or until the participants started an investigational agent or new therapy for treatment of prostate cancer or until any other discontinuation criterion was met. Eligible participants who received enzalutamide during double-blind treatment period and provided informed consent to take part in open-label period continued to receive 160 mg enzalutamide orally once daily in open-label period until disease progression, unacceptable toxicity or any other discontinuation criteria were met. ADT (either bilateral orchiectomy or Luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
Risk Summary

There are no available data on MULPLETA in pregnant women to inform the drug-associated risk. In animal reproduction studies, oral administration of lusutrombopag to pregnant rats during organogenesis and the lactation period resulted in adverse developmental outcomes. These findings were observed at exposures based on AUC that were substantially higher than the AUC observed in patients (approximately 89 times) at the recommended clinical dose of 3 mg once daily. Advise pregnant women of the potential risk to a fetus (see Data).

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the general population in the United States, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

In an embryo-fetal development study in rats, lusutrombopag was orally administered during organogenesis at doses of 4, 12.5, 40, and 80 mg/kg/day. Low body weight and a decrease in the number of ossified sternebrae were noted in fetuses at 80 mg/kg/day (approximately 251 times the AUC observed in patients at the recommended clinical dose of 3 mg once daily). Minor skeletal variations (supernumerary ribs) were observed at doses of 4 mg/kg/day (approximately 23 times the AUC observed in patients at the recommended clinical dose of 3 mg once daily). 

In an embryo-fetal development study in rabbits following oral administration of lusutrombopag at doses up to 1000 mg/kg/day, no effect of lusutrombopag was observed on any parameter of embryo-fetal development.

In a pre- and postnatal development study in rats at oral doses of 1, 4, 12.5, and 40 mg/kg/day, there were adverse effects of lusutrombopag on postnatal development at 40 mg/kg/day (approximately 230 times the AUC observed in patients at the recommended clinical dose of 3 mg once daily). The effects included prolongation of the gestation period in dams, low viability before weaning, delayed postnatal growth (delayed negative geotaxis, delayed eyelid opening, or low pup body weight), abnormal clinical signs (prominent annular rings on the tail after weaning), low fertility index, a low number of corpora lutea or implantations, and increased pre-implantation loss. The incidence of short thoracolumbar supernumerary ribs on postnatal Day 4 of F1 pups was high at doses of 12.5 mg/kg/day or more (approximately 89 times the AUC observed in patients at the recommended clinical dose of 3 mg once daily).
A method, apparatus, and non-transitory computer-readable medium are provided for image processing of medical images. The method may include receiving one or more medical images. Tissue regions may be identified in each of the one or more medical images. The method may include generating patches associated with respective identified tissue regions. A patch tumor burden (TMB) score may be predicted for each of the patches based on a neural network model, wherein the neural network model is trained using a distribution smoother and a weighted loss function. The method may also include a tumor burden score being generated for each of the one or more medical images based on the patch tumor burden score for patches associated with the respective identified tissue regions in respective medical images from the one or more medical images.
Arm 2. The subjects will receive automated "coaching"by SMS.The subjects will be recruited from the general population reporting not to be associated with the University Hospital of North Norway and randomized to arm 1 or 2.
Participants receive Q702 orally (PO) once daily (QD) on days 1-7 and 15-21 of each cycle. Azacitidine intravenously (IV) over 10-40 minutes or subcutaneously (SC) on days 1-7 of each cycle and venetoclax PO QD on days 1-21 or days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants also undergo collection of blood samples and bone marrow aspiration and/or biopsy throughout the trial.
PURPOSE:To obtain the titled improving agent composed of a component soluble in n-hexane and insoluble in acetone, by treating the oil cake produced in the refining of linseed oil with n-hexane and acetone. CONSTITUTION:The oil cake produced in the refining of linseed oil is dehydrated by mixing with e.g. sodium sulfate or by freeze-drying, etc. The dehydrated product is mixed with n-hexane to extract the lipid component. After removing n-haxane, the residue is added with acetone, and filtered to collected the insoluble component. Acetone is removed from the product to obtain a serum lipid metabolism improving agent containing the acetone-insoluble component as an active component. The acetone-insoluble component is mixed with an alcohol, and fractionated into the soluble component and the insoluble component. Ethanol is removed from both components, and a serum lipid metabolism improving agent can be obtained from the ethanol-soluble component and the ethanol- insoluble component.
The use of Trecator alone in the treatment of tuberculosis results in rapid development of resistance. It is essential, therefore, to give a suitable companion drug or drugs, the choice being based on the results of susceptibility testing. However, therapy may be initiated prior to receiving the results of susceptibility tests as deemed appropriate by the physician. Ethionamide should be administered with at least one, sometimes two, other drugs to which the organism is known to be susceptible (see INDICATIONS AND USAGE). Drugs which have been used as companion agents are rifampin, ethambutol, pyrazinamide, cycloserine, kanamycin, streptomycin, and isoniazid. The usual warnings, precautions, and dosage regimens for these companion drugs should be observed.

Patient compliance is essential to the success of the anti-tuberculosis therapy and to prevent the emergence of drug-resistant organisms. Therefore, patients should adhere to the drug regimen for the full duration of treatment. It is recommended that directly observed therapy be practiced when patients are receiving anti-tuberculous medication. Additional consultation from experts in the treatment of drug-resistant tuberculosis is recommended when patients develop drug-resistant organisms.
Adult patients suffering from chronic subjective non-pulsatile primary unilateral or bilateral tinnitus for at least 6 months will be included in the study. Patients will be randomly assigned using a random number generation randomization method into rTMS stimulation group (group 1), sham stimulation group (group 2) and group with medicament therapy only (group 3). Dorsolateral prefrontal cortex (frequency 25 Hz; 300 pulses; 80% resting motor threshold=RMT) and primary auditory cortex on both sides (1 Hz; 1000 pulses; 110% RMT) will be stimulated in patients in rTMS stimulation group for 5 consecutive days. Both the patients and outcome assessor were blinded to the intervention group in which the patients (rTMS and shame stimulation group) belonged to. Medicament therapy in group 3 will consist of ginkgo biloba extract EGb 761 once a day for 6 months. There will be no medicament therapy for tinnitus in group 1 and 2. Tinnitus reaction questionnaire (TRQ), tinnitus handicap questionnaire (THQ), tinnitus handicap inventory (THI), Beck Depression Inventory (BDI), pure-tone audiometry with Fowler scoring of hearing loss and tinnitus analysis will be used for evaluation of tinnitus in all patients. Data will be recorded on the day patient is included in the study, during follow-up after 1 month and 6 months. Descriptive statistics, such as the arithmetic mean, standard deviation, and absolute and relative frequency tables, will be used for data processing. The Pearson's chi-squared test, Fisher's exact test, Kruskal-Wallis test and analysis of variance will be used for comparison. The statistical tests will be assessed using a significance level of 5%.
The invention comprises compounds of the general formula <FORM:1007584/C2/1> wherein R is hydrogen or C1 to C8 alkyl, R1\t is hydrogen, C1 to C4 alkyl, phenyl, hydroxyphenyl, alkoxyphenyl wherein alkoxy is of 1 to 4 carbon atoms, or halophenyl, R2 is hydrogen, alkanoyl of from 1 to 4 carbon atoms, benzyl or halobenzyl which can be substituted with alkyl or alkoxy of 1 to 4 carbon atoms, or alkyl of from 1 to 4 carbon atoms, R3 is hydroxy, benzyloxy, halogen, or alkyl or alkoxy of from 1 to 4 carbon atoms, and n is zero, 1 or 2. The compounds may be prepared by subjecting the 5-oxo group of a compound of the general formula <FORM:1007584/C2/2> wherein R, R1, R2, R3 and n are as defined above, to a Huang-Minlon reduction and, in the case where R2 in the starting material represents an alkanoyl group, optionally N-acylating the acid so produced.  The acids may be esterified by conventional procedures, for example, via the acid chlorides, and the resultant esters may be purified and then hydrolysed to the acids, resulting in upgrading of the acids.  The compounds of the invention, wherein R is H, may be decarboxylated by heating to give compounds of the general formula. <FORM:1007584/C2/3> wherein R1, R2, R3 and n are as defined above. The compounds of the invention, wherein R is H, may also be esterified in accordance with U.S.A.  Specification 2,220,521, to form betathiocyanoethyl esters. The Huang-Minulon reduction is performed by conversion of the acid or the ester to the corresponding salt, followed by reduction with hydrazine hydrate. Many suitably values of R, R1, R2 and R3 are specified.  Examples are given, including examples of the hydrogenolysis of acids containing a 6- or 8-benzyloxy substituent to give the corresponding free hydroxy compounds.ALSO:Sun-screen lotions may incorporate, as ultraviolet absorbents, compounds of the general formula <FORM:1007584/A5-A6/1> wherein R is hydrogen or C1 C8 alkyl, R, is hydrogen, C1 to C4 alkyl, phenyl, hydroxyphenyl, alkoxyphenyl wherein alkoxy is of 1 to 4 carbon atoms, or halophenyl, R2 is hydrogen, alkanoyl of from 1 to 4 carbon atoms, benzyl or halobenzyl which can be substituted with alkyl or alkoxy of 1 to 4 carbon atoms, or alkyl of from 1 to 4 carbon atoms, R3 is hydroxy, benzyloxy, halogen, or alkyl or alkoxy of from 1 to 4 carbon atoms, and n is zero, 1 or 2 (see Division C2).